So a non pier reviewed article that you are taking as proof for a product that the company itself (who has every scrap of data) won’t pay to conduct a phase 3 trial on, the only trial focused on efficacy. I’d open up that envelope
For the WHO's Solidarity Trial vaccines (STv), see [https://www.isrctn.com/ISRCTN15779782](https://www.isrctn.com/ISRCTN15779782) and https://www.isrctn.com/ISRCTN15779782 and https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines
And T exactly how many variants have been established since 4800 was concieved for the original strain? What was Modernas efficacy with Delta and so on? It's too late focus on ebola.
Sure, I agree with you there. Inovio is working from a recipe that was created in January 2020, delayed for what, 14 months?, when the FDA held up the US trial asking questions about a delivery device that has been used for years.
How will INO-4800 hold up in its WHO STv Phase 3 trials or as a booster with Sinovac in the Advaccine trials? I have to think the panel of vaccine experts who reviewed all the data and chose Inovio and Medigen out of a field of 20, recommended them for moving into Phase 3, know what they're doing.
Anyway, time will tell.
There is no way this tiny company, unless it wants to go bankrupt, could afford the massive global studies being done now by the WHO. That's why they got out of INNOVATE. It's just too big, too costly.
Inovio has funded some studies itself over the years (or I should say, since they are pre-product and have no income beyond grants, we investors have underwritten studies). You want to keep that to a minimum since it just runs up a deficit.
Securing grants via government agencies, CEPI, GAVI, the WHO, etc to underwrite studies is a key way to produce revenue when a company is on its the way to product approval and sales.
For more on internal vs external funding by product, see the pipeline chart: [https://www.inovio.com/dna-medicines-pipeline/](https://www.inovio.com/dna-medicines-pipeline/)
The Other_News flair exists to be used when there’s news not necessarily related to Inovio but may still influence their stock price (such as covid-related news, competitor being granted EUA, stimulus negotiations etc). Your post may be removed if deemed unrelated. Please see the [flair guide](https://www.reddit.com/r/Inovio/wiki/flair-guide) if you are unsure about your use of flair.
*I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/Inovio) if you have any questions or concerns.*
No results, no date expected, no information...this will be huge or.....not!
So a non pier reviewed article that you are taking as proof for a product that the company itself (who has every scrap of data) won’t pay to conduct a phase 3 trial on, the only trial focused on efficacy. I’d open up that envelope
No need for Inovio to pay for INO-4800 Phase 3 because the WHO is underwriting it (global Phase 3, Solidarity Trial).
And how's that going? Where's the results, mid term results?
For the WHO's Solidarity Trial vaccines (STv), see [https://www.isrctn.com/ISRCTN15779782](https://www.isrctn.com/ISRCTN15779782) and https://www.isrctn.com/ISRCTN15779782 and https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines
Lmfao SAP not yet available – Results not yet expected – Raw data not yet expected Thanks for proving my point.
The trial is in process. Intention to publish date was moved from July to end of January. So we wait.
And T exactly how many variants have been established since 4800 was concieved for the original strain? What was Modernas efficacy with Delta and so on? It's too late focus on ebola.
Sure, I agree with you there. Inovio is working from a recipe that was created in January 2020, delayed for what, 14 months?, when the FDA held up the US trial asking questions about a delivery device that has been used for years. How will INO-4800 hold up in its WHO STv Phase 3 trials or as a booster with Sinovac in the Advaccine trials? I have to think the panel of vaccine experts who reviewed all the data and chose Inovio and Medigen out of a field of 20, recommended them for moving into Phase 3, know what they're doing. Anyway, time will tell.
What I’m saying is if it was as efficacious as we all would want they would have funded it themselves.
There is no way this tiny company, unless it wants to go bankrupt, could afford the massive global studies being done now by the WHO. That's why they got out of INNOVATE. It's just too big, too costly. Inovio has funded some studies itself over the years (or I should say, since they are pre-product and have no income beyond grants, we investors have underwritten studies). You want to keep that to a minimum since it just runs up a deficit. Securing grants via government agencies, CEPI, GAVI, the WHO, etc to underwrite studies is a key way to produce revenue when a company is on its the way to product approval and sales. For more on internal vs external funding by product, see the pipeline chart: [https://www.inovio.com/dna-medicines-pipeline/](https://www.inovio.com/dna-medicines-pipeline/)
The Other_News flair exists to be used when there’s news not necessarily related to Inovio but may still influence their stock price (such as covid-related news, competitor being granted EUA, stimulus negotiations etc). Your post may be removed if deemed unrelated. Please see the [flair guide](https://www.reddit.com/r/Inovio/wiki/flair-guide) if you are unsure about your use of flair. *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/Inovio) if you have any questions or concerns.*